861
Unp eceden ed deoxygena ion a C-7 o he
ansami ocin co e du ing mu asyn he ic
bio ans o ma ions
Tobias Knobloch1, Ge ald D äge 1, We a Collisi2, Flo enz Sasse2
and And eas Ki schning*1
Full Resea ch Pape Open Access
Add ess:
1Ins i u e o O ganic Chemis y and Cen e o Biomolecula D ug
Resea ch (BMWZ), Leibniz Uni e si y Hanno e , Schneide be g 1b,
30167 Hanno e , Ge many and 2Depa men o Chemical Biology,
Helmhol z Cen e o In ec ious Resea ch (HZI), Inho ens aße 7,
D-38124 B aunschweig, Ge many
Email:
And eas Ki schning* - [email p o ec ed]
* Co esponding au ho
Keywo ds:
ansami ocins; an ibio ics; an i umo agen s; mu asyn hesis; na u al
p oduc s
Beils ein J. O g. Chem. 2012, 8, 861–869.
doi:10.3762/bjoc.8.96
Recei ed: 23 Ap il 2012
Accep ed: 16 May 2012
Published: 11 June 2012
This a icle is pa o he Thema ic Se ies "Biosyn hesis and unc ion o
seconda y me aboli es".
Gues Edi o : J. S. Dickscha
© 2012 Knobloch e al; licensee Beils ein-Ins i u .
License and e ms: see end o documen .
Abs ac
We desc ibe he unp eceden ed o ma ion o six ansami ocin de i a i es ha a e deoxygena ed a C-7 o he ansami ocin co e,
ob ained du ing e men a ion expe imen s by employing a a ie y o Ac inosynnema p e iosum mu an s and mu asyn he ic
app oaches. We sugges ha he o ma ion o hese de i a i es is based on elimina ion a C-7/C-8 ollowed by educ ion(s) o he
in e media e enone. In bioac i i y es s, only ansami ocin de i a i es bea ing an es e side chain a C-3 showed s ong
an ip oli e a i e ac i i y.
861
In oduc ion
Na u al p oduc s s ill play an impo an ole as lead s uc u es
o he ea men o in ec ious diseases and cance . Howe e ,
na u al p oduc s ha e los some o hei a ac ion o he de el-
opmen o pha maceu icals because o hei s uc u al
complexi y and he di icul ies associa ed wi h accessing
analogues o s uc u e–ac i i y ela ionship s udies. To al syn-
hesis app oaches a e s ill a ou de o ce and a e ha dly
employed, while commonly semisyn hesis as well as bio echno-
logical app oaches a e widely pu sued in indus ial esea ch
[1-3]. In es iga ions in o he biosyn hesis o na u al p oduc s
ha e no only allowed us o unde s and he syn he ic p inciples
ha na u e pu sues, bu ha e also p o ided ools, mainly based
on gene ic enginee ing, which can be exploi ed in na u al p od-
uc syn hesis [4].
P oduce s ains gene ically blocked in he biosyn hesis o
impo an and complex na u al p oduc s can se e as such new
ools. The syn he ic concep based on hese blocked mu an s is
Beils ein J. O g. Chem. 2012, 8, 861–869.
862
Scheme 1: Summa y o ansami ocin biosyn hesis and s uc u e o he ela ed ansamycin an ibio ic geldanamycin (6).
e med “mu a ional biosyn hesis”, o in sho mu asyn hesis,
and i elies on he cellula up ake o modi ied biosyn he ic
in e media es, some imes e med mu asyn hons, and hei
inco po a ion in o complex seconda y me aboli es [5-7].
When making use o mu an s ha a e blocked in ea ly s ages o
a gi en biosyn hesis pa hway, he concep o mu asyn hesis
may be compa ed o a (pa ial) na u al p oduc o al syn hesis.
When u he modi ica ion o an ad anced biosyn he ic in e -
media e wi h an es ablished co e s uc u e owa ds bioac i e
na u al p oduc s and analogues is conduc ed, mu asyn hesis
may be ega ded as he “endgame” o a o al syn hesis [4].
The ansami ocins (may ansinoids) 3–5 a e ideally sui ed o
mu asyn he ic modi ica ions and he c ea ion o new analogues
because hey a e highly po en an i umo ac i e compounds ha
inhibi he g ow h o di e en leukemia cell lines as well as
human solid umo s a e y low concen a ions (10−3 o
10−7 µg/mL) [8]. In con as o colchicine, may ansinoids such
as ansami ocins bind o β- ubulin monome s a a si e o e lap-
ping he inca alkaloid binding si e [9].
Recen ly, we disclosed se e al mu asyn he ic s udies aimed a
he p oduc ion o de i a i es o ansami ocins 3–5 [10-12] as
well as o geldanamycin (6), u ilizing mu an s ains o
Ac inosynnema p e iosum, he ansami ocin p oduce [13-17],
and S ep omyces hyg oscopicus, he geldanamycin p oduce
[18,19]. These enginee ed s ains a e unable o biosyn hesize
3-amino-5-hyd oxybenzoic acid (1) [20], he common s a e
uni o bo h polyke ide syn hases (PKS) (Scheme 1). These
assembly-line- ype mul ienzymes a e esponsible o se ing up
he comple e ca bon backbone o bo h ansamycin an ibio ics
[21-24].
Mo e p ecisely, he biosyn hesis o ansami ocins elies on a
ype I modula polyke ide syn hase (PKS), wi h 3-amino-5-
hyd oxybenzoic acid (1, AHBA) [20] as he s a e uni ol-
lowed by chain ex ension by one “glycola e”, h ee p opiona e
and h ee ace a e uni s. The las PKS module holds seco-
p oansami ocin, which is eleased and cyclized, p esumably by
an ansamycin amide syn hase (Asm9) [21-24], o yield he
19-membe ed mac ocyclic lac am p oansami ocin (2).
P oansami ocin (2) is ans o med in o bioac i e compounds
3–5 by a se o pos -PKS ailo ing s eps, ollowing a p ede e -
mined, only pa ly lexible logic (Scheme 1) [16].
Complemen ing ou s udies wi h mu an s ain A. p e iosum
HGF073, blocked in he biosyn hesis o he PKS s a e uni
AHBA 1 [13-16], we ecen ly epo ed he use o a mu an o
A. p e iosum blocked in Asm12 (chlo ina ion) and Asm21
Beils ein J. O g. Chem. 2012, 8, 861–869.
863
Figu e 1: Fe men a ion p oduc s, p oansami ocin (2) and de i a i es 7–9, o he Asm12 and Asm21-blocked (chlo ina ion, ca bamoyla ion) mu an
s ain A. p e iosum Δasm12/21 (yields gi en as isola ed p oduc pe olume o e men a ion b o h) [17].
(ca bamoyla ion) and he e o e p oducing p oansami ocin (2) in
good yield (up o 106 mg/L o e men a ion b o h) [17]. Addi-
ionally, we isola ed small amoun s o O-me hyl p oansami-
ocin 7 (2.3 mg/L), 10-epi-p oansami ocin 8 (3.5 mg/L) and wo
dias e eome ic byp oduc s 9a and 9b (7.6 mg/L; 1:1 a io) om
he e men a ion b o h o A. p e iosum Δasm12/21 (Figu e 1).
We also showed ha none o hese p oansami ocin de i a i es
exhibi an ip oli e a i e ac i i y.
He ein, we desc ibe he unp eceden ed o ma ion o ansami-
ocin de i a i es ha a e deoxygena ed a C-7 o he ansami-
ocin co e, ob ained by us du ing e men a ion expe imen s
using a a ie y o A. p e iosum mu an s and mu asyn he ic
app oaches.
Resul s and Discussion
In he cou se o ou well-es ablished mu asyn hesis expe i-
men s wi h A. p e iosum HGF073, a mu an ha is unable o
p oduce he essen ial s a e uni AHBA (1) by i sel , we
achie ed he gene a ion o se e al no el ansami ocin de i a-
i es, among o he hings, based on he simple mu asyn hon
3-amino-5-chlo obenzoic acid (10, Scheme 2).
Wi h he excep ion o p oansami ocin analogue 11a, all new
me aboli es we e isola ed on a p epa a i e scale and ully cha -
ac e ized. These compounds co espond o he known s epwise
sequence o pos ke ide syn hase ailo ing ans o ma ions, and
hose p oduc s and simila compounds ha e been epo ed by us
be o e [16]. As e iden om he a ie y o compounds isola ed,
p oansami ocin analogues esul ing om supplemen a ion o
AHBA analogue 10 o A. p e iosum HGF073 we e no e i-
cien ly p ocessed by he enzymes in ol ed in pos -PKS
ailo ing. In addi ion o he o dina y compounds 11a–e, he
expe imen yielded h ee compounds o an unp eceden ed ype
(11 –h) whose appea ance could no be a ibu ed o he known
ailo ing ans o ma ions. He ein, we now desc ibe o he i s
ime he isola ion and cha ac e iza ion o compounds 11 –h
sha ing, in con as o all o he (p o)ansami ocin de i a i es
known so a , he common ea u e o deoxygena ion a C-7. In
addi ion, p oansami ocin de i a i es 11g–h a e no able o hei
C-9 alcohol, while 11h shows addi ional ca bamoyla ion o he
unusual alcohol moie y. The ex ao dina y p oansami ocin
de i a i es 11 –h we e ully cha ac e ized, excep o he con-
igu a ion a C-9 in 11g and 11h (single dias e eome ). O e lap
wi h o he signals in he 1H NMR spec a hampe ed comple e
assignmen o all coupling cons an s a C-9 excep o J9,10 =
7.2 Hz, which, howe e , is no diagnos ic.
In con inua ion o ou expe imen s wi h ad anced biosyn he ic
in e media es, such as p oansami ocin (2) [25] and seco-acid
de i a i es [26,27] se ing as mu asyn hons in expe imen s
wi h ea ly-s age-blocked mu an s, we also es ed he unusual
me aboli es 9a and 9b [17] as p ecu so s o u he p ocessing
by he AHBA(−)-mu an o he ansami ocin p oduce
(Scheme 3).
O iginally ob ained by e men a ion o a mu an blocked o he
g ea es ex en in he pos -PKS ans o ma ion sequence
(A. p e iosum Δasm12/21) [17], i was ques ionable whe he
hese compounds, di e ing subs an ially om p oansami ocin
(2) bo h by a ea anged diene sys em and an alcohol moie y a
C-14, would be accep ed by he ailo ing enzymes. Su p isingly,
when he ea anged oxida ion p oduc s 9a and 9b we e each
supplemen ed o cul u es o A. p e iosum HGF073, new p od-
uc s we e o med. While he ca bamoyla ed de i a i e 12
esul ing om bio ans o ma ion o alcohol 9b can be a ib-
u ed o he ac i i y o he ca bamoyl ans e ase Asm21, he eby
p o iding an indica ion pe aining o i s subs a e lexibili y,
p oduc s 13a and 13b ob ained om bo h expe imen s a e mo e
unusual and di e om he s a ing ma e ial by being deoxy-
gena ed a C-7.
Howe e , he s uc u e o compound 12 s ongly con as s wi h
all o he o he 7-O-ca bamoyla ed (p o)ansami ocin de i a-
i es ha we ha e ob ained wi h his kind o eeding expe i-
men so a [17]. In he case o compound 12, he ca binol-
Beils ein J. O g. Chem. 2012, 8, 861–869.
864
Scheme 2: Mu asyn he ic p epa a ion o ansami ocin de i a i es 11a–h by using 3-amino-5-chlo obenzoic acid (10) as a mu asyn hon (yields in %
a e calcula ed wi h e e ence o he amoun o mu asyn hon 10 ed).
amide moie y is no p esen in a cyclic hal aminal o m (δC-9
~197 ppm ins ead o ~82 ppm), despi e he ac ha he ke o
g oup a C-9 is s ill p esen . This esul may be a ibu ed o he
ke o g oup a C-9 being in conjuga ion wi h he diene sys em,
esul ing in a educed ac i i y o he ca bonyl g oup and an al-
e a ion o he mac olac am ing con o ma ion.
We based he de e mina ion o deoxygena ion a C-7 in 13a and
13b on MS da a and he appea ance o a seconda y ca bon a om
in exchange o he e ia y ca binol a C-7 on phase-sensi i e
1H–13C-co ela ion NMR spec a (HSQC). I needs o be no ed
ha NOE-analysis combined wi h molecula modeling did no
allow elucida ion o he absolu e con igu a ion a C-14 o he
new de i a i es 13a and 13b, as i did no allow o he s a ing
compounds 9a and 9b [17].
In o de o shed ligh on he sequence o e en s leading o
deoxygena ion, he ca bamoyla ed de i a i e 12 was again ed
o a cul u e o A. p e iosum HGF073, and he o ma ion o new
p oduc s was analyzed by UPLC-HRMS o he pa ially pu i-
ied c ude ex ac (Scheme 3). Indeed, he expec ed deoxy-
gena ed p oduc 13b could be de ec ed, bu was also accompa-
nied by he o ma ion o alcohol 9b. Compound 9b may ei he
ha e esul ed om Michael addi ion o wa e o he suspec ed
Beils ein J. O g. Chem. 2012, 8, 861–869.
865
Scheme 3: Mu asyn he ic bio ans o ma ion o p oansami ocin de i a i es 9a and 9b wi h AHBA(−) mu an A. p e iosum HGF073 (s a ing ma e ials
could be eisola ed: 9a: 77% eisola ed, 9b: 23% eisola ed).
Scheme 4: Fe men a ion p oduc s 14–16 o acyl ans e ase Asm19-blocked mu an A. p e iosum HGF059 (Δasm19) (yields gi en as isola ed p od-
uc pe olume o e men a ion b o h).
in e media e enone 17 (see la e in Scheme 5) o om
hyd oly ic clea age o he ca binolamide 12.
A blocked mu an o A. p e iosum ha is unable o ca y ou
acyla ion o he C-3 alcohol o he ca bamoyla ed p oansami-
ocin de i a i e p ecu so due o gene ic inac i a ion o he acyl
ans e ase Asm19, was epo ed by Floss e al. [21,28]. I was
known ha mu an s ain A. p e iosum HGF059 p oduces he
expec ed ansami ocin de i a i e 14 in good yield (Scheme 4)
[28]. Besides he es e side chain, compound 14 also lacks he

Beils ein J. O g. Chem. 2012, 8, 861–869.
866
Scheme 5: Possible mechanism o deoxygena ion a C-7 o p oansami ocin de i a i es.
epoxy unc ionali y and he N-me hyl g oup. These wo
ailo ing s eps inalize he biosyn hesis o ansami ocin P-3
(AP-3, 4) and occu only a e acyla ion has aken place
(Scheme 1).
While examining he e men a ion ex ac o byp oduc s we
we e able o iden i y wo new me aboli es, 15 and 16. Fo ma-
ion o compound 15 can be aced back o ine icien chlo ina-
ion, a phenomenon ha we ha e encoun e ed be o e in o he
eeding expe imen s wi h p oansami ocin [25]. Mo e unusual is
me aboli e 16, which is ye ano he example o a case in which
deoxygena ion a C-7 has aken place.
In summa y, deoxygena ion may occu when he AHBA-
blocked mu an A. p e iosum HGF073 o he acyl ans e ase
Asm19-blocked mu an A. p e iosum HGF059 a e employed,
whe eas he educ ion p ocess does no occu wi h he blocked
mu an A. p e iosum ∆asm12/21. The majo di e ence be ween
hese h ee mu an s is he p esence (HGF073, HGF059) o
absence (Δasm12/21) o he ca bamoyl ans e ase Asm21.
Ca bamoyla ion o p oansami ocin de i a i es a C-7 (e.g. 11a,
9a/b and 7) in oduces a ai ly good lea ing g oup β-posi ioned
o he ke o g oup, he eby acili a ing elimina ion o enones 17
(Scheme 5).
In he case o compound 12, which p edominan ly exis s in a
o m lacking he ypical cyclized ca binolamide moie y, he C-9
ke o g oup can p ese e i s elec onic p ope ies, hus acili-
a ing he elimina ion s ep. Finally, he ac i i y o a ailo ing
educ ase, which in all likelihood is no pa o he PKS,
ca alyzes he educ ion o he α,β-unsa u a ed bond, yielding he
deoxygena ed de i a i es (11 , 13a/b, 16). Dias e eoselec i e
educ ion o he C-9 ke o g oup and ca bamoyla ion o in e -
media e 11 would hen esul in compounds 11g and 11h, es-
pec i ely.
A ac o con ibu ing o he o ma ion o deoxygena ed
p oansami ocin de i a i es is likely he usage o he ca bamoyl-
a ed p ecu so s by he Asm19 acyl ans e ase. Acyla ion is a
c ucial bo leneck s ep in he o he wise pa ly lexible sequence
o pos -PKS ans o ma ions. When his s ep canno occu due
o he absence o an ac i e acyl ans e ase (as in A. p e iosum
HGF059), o i he ans o ma ion is ine icien (e.g., com-
pound 11b) o e en nonexis en due o an unusual subs a e
(e.g., compound 12), ca bamoyla ed in e media es accumula e.
Indeed, he ca bamoyla ed p oduc 11b was he majo p oduc
o he mu asyn hesis expe imen wi h mu asyn hon 10. The
ca bamoyla ed compounds may hen be channeled in o he
pa hway leading o deoxygena ed p oduc s. Depending on he
subs a e, his p ocess may be qui e e icien . Fo ins ance, no
ca bamoyla ed p oduc could be isola ed a e he bio ans o -
ma ion o compound 9a, indica ing an e icien ans o ma ion
o he suspec ed ca bamoyla ed in e media e o he inal p od-
uc 13a.
All (p o)ansami ocin de i a i es ully cha ac e ized by NMR
we e also subjec ed o in i o biological es ing wi h di e en
human cell lines de i ed om umo s o he umbilical ein. The
esul s om hese es s a e gi en as alues o he hal -maximal
inhibi o y concen a ion o he espec i e ansami ocin de i a-
Beils ein J. O g. Chem. 2012, 8, 861–869.
867
Table 1: An ip oli e a i e ac i i y IC50 [nmol/L] o 11c–e in compa ison o AP-3 (4).a
compound
cell line
U-937 A-431 SK- OV-3 PC-3 MCF-7 HUVEC
AP-3 (4) 0.01 0.08 0.05 0.06 n.d. 0.02
11c 0.5 1.58 0.66 0.30 0.90 0.32
11d 0.05 0.10 0.05 0.16 0.11 0.08
11e 0.18 0.35 0.21 0.53 0.41 0.21
aValues shown a e means o wo de e mina ions in pa allel; human cell lines: U-937 (his iocy ic lymphoma), A-431 (epide moid ca cinoma), SK-OV-3
(o a y adenoca cinoma), PC-3 (p os a e adenoca cinoma), MCF-7 (b eas adenoca cinoma), HUVEC (umbilical ein endo helial cells); n.d. = no
de e mined.
i es in compa ison o he “gold s anda d” ansami ocin P-3 (4,
Table 1). As expec ed [14], all (p o)ansami ocin de i a i es
lacking he es e side chain a C-3 (11b, 11g–h, 12–16) do no
show any an ip oli e a i e ac i i y (IC50 > 800 nM) o a leas
wo o he cell lines lis ed in Table 1.
Compounds 11c–e, bea ing he es e side chain a C-3, p edomi-
nan ly showed ac i i ies in he pM ange. As seen also wi h
AP-3 (4), he e is no signi ican di e ence be ween cance ous
and heal hy cells. The mos ac i e compound was he N-me hyl
de i a i e 11d, which eached he ac i i y o he s anda d AP-3
(4) o selec ed cell lines.
Conclusion
In conclusion, we disclose he isola ion and chemical and
an ip oli e a i e ac i i y cha ac e iza ion o se e al no el
ansami ocin de i a i es ha a e deoxygena ed a C-7. We used
h ee di e en A. p e iosum mu an s and a a ie y o mu asyn-
he ic app oaches. These p elimina y s udies on he deoxygena-
ion a C-7 sugges ha i occu s by elimina ion a C-7/C-8 a e
ca bamoyla ion has aken place, ollowed by educ ion medi-
a ed by an unknown educ ase, which is no pa o he main
assembly line PKS. As expec ed, all ansami ocin compounds
bea ing he es e side chain a C-3 p edominan ly showed ac i -
i ies in he pM ange.
Expe imen al
Analy ical de ails a e gi en in he Suppo ing In o ma ion
File 1.
Cul i a ion
In gene al, cul i a ion o mic obial s ains on aga pla es was
conduc ed in a He aeus incuba o a 30 °C, while cul i a ion in
a shake lask was pe o med in a mul ile el New B unswick
Scien i ic Inno a 4900 gy a o y mul i-shake a 200 pm a
29 °C.
Unless o he wise no ed, he cul i a ion media we e p epa ed
using dis illed wa e and s e ilized by au ocla ing: YMG
medium – 10 g/L mal ex ac (Sigma), 4 g/L yeas ex ac
(Bac o), 4 g/L D(+)- glucose∙H2O; YMG aga – YMG medium
plus 22 g/L aga (Bac o); K-medium [29], basal composi ion
( inal s a concen a ion in he main cul u e co esponds o 5/6
o he alues gi en o his medium due o dilu ion) – 60 g/L
dex in om maize s a ch (Fluka), 30 g/L D(+)-mal ose∙H2O
(Fluka), 5.25 g/L co onseed lou (P o lo), 5 g/L CaCO3,
4.5 g/L yeas ex ac (Bac o), 300 mg/L K2HPO4 (Fluka, T ace-
Selec ), 2 mg/L FeSO4∙7H2O. K-medium, addi i e – au o-
cla ed and added sepa a ely: 3 g/L L- aline ( inal s a concen-
a ion in he main cul u e, om a 3% (w/ ) s ock solu ion).
A. p e iosum HGF073 is a eplica e o s ain HGF056 epo ed
in [22].
Fe men a ion o A. p e iosum s ains
A. p e iosum s ains (HGF073, HGF059, Δasm12/21) we e
s o ed as spo e suspensions in 40% ( / ) glyce ol/wa e a
−80 °C, and used o he inocula ion o YMG aga pla es.
Following incuba ion o he pla es o 4 d a 30 °C, 5–8 well-
spo ula ed colonies we e ans e ed o a 1.5 mL ube cha ged
wi h 1 mL o s e ile dis illed wa e and illed o app ox. 50%
heigh wi h s e ile glass beads (Ø = 2 mm, washed wi h dilu e
hyd ochlo ic acid). A e o ex-mixing, he esul ing suspen-
sion was used o he inocula ion o p ecul u es in bo om-
ba led 250 mL E lenmeye lasks cha ged wi h YMG medium
(50 mL pe lask, wi h addi ional s eel sp ing). P ecul u es we e
shaken o 2 d a 29 °C be o e inocula ion o main p oduc ion
cul u es (1/15 dilu ion). Cul i a ions we e pe o med in
K-medium wi h addi i es – 42 mL K-medium wi h L- aline,
3 mL p ecul u e and one d op o SAG 471 an i- oam (GE Baye
Silicones) [30] – by using nonba led 250 mL E lenmeye
lasks ( inal olume: 35–60 mL pe lask, wi h addi ional s eel
sp ing). Shaking was con inued a 29 °C o a o al cul i a ion
ime o 7–10 days.
Beils ein J. O g. Chem. 2012, 8, 861–869.
868
Fo de ec ion o no el p oduc s om es cul u es, samples o
he cul u e b o h (200 μL) we e mixed wi h e hanol (200 μL),
cen i uged (20800g, 3 min, 4 °C) and he clea supe na an
subjec ed o UPLC-ESIMS analysis. Failing de ec ion o no el
p oduc s, he cul u e b o h was ex ac ed h ee imes wi h e hyl
ace a e, d ied o e MgSO4, concen a ed in acuo, and il e ed
o e silica gel wi h e hyl ace a e, and he sol en was emo ed
in acuo. The esidue was dissol ed in me hanol (1 mL) and
subjec ed o UPLC-ESIMS analysis.
Fo isola ion o no el p oduc s om (la ge-scale) e men a ions,
he combined e men a ion b o h was ex ac ed wi h e hyl
ace a e as desc ibed abo e, and he c ude ex ac subjec ed o a
sequence o ch oma og aphic pu i ica ions (Suppo ing In o -
ma ion File 1).
Mu asyn hesis wi h A. p e iosum HGF073
In mu asyn hesis expe imen s wi h A. p e iosum HGF073,
p oduc ion cul u es we e shaken o 2 d a e inocula ion (see
abo e) be o e mu asyn hons we e added (9a, 9b, 10 o 12). Fo
no el mu asyn hons, p oduc i i y o he s ain was i s moni-
o ed by pa allel eeding o mu asyn hons o which accep ance
was known (e.g., he na u al s a e building block: 3-Amino-5-
hyd oxybenzoic acid, hyd ochlo ide sal (1)). Mu asyn hons
we e dissol ed in DMSO/wa e [p e e ably 1:1; olume o
eeding solu ion no exceeding 10% ( / ) wi h espec o he
ecipien cul u e] and s e ilized by il a ion.
Mu asyn hon 10 (1.25 mmol/L o e men a ion b o h) was
added o p oduc ion cul u es wi h a combined olume o
945 mL con inuously (d op-wise) o e he ime-cou se o 3.5 d,
by using au ocla able, sy inge pump-d i en eeding capilla ies
– B ain ee Scien i ic BS-9000-8 sy inge pump wi h Upchu ch
Scien i ic high-pu i y Te lon® PFA ubing (1/16” OD, 0.1” ID)
and Te zel® connec o s.
Bio ans o ma ion o he p oansami ocin de i a i es 9a, 9b and
12 was ca ied ou by supplemen ing a p oduc ion cul u e o
A. p e iosum HGF073 (45 mL inal olume; K-medium; see
abo e) wi h he espec i e de i a i e [9a/b (each: 4.5 mg,
9.8 µmol, dissol ed in 2 mL DMSO:H2O = 1:1); 12 (0.1 mg,
0.2 µmol, dissol ed in 1 mL DMSO)] in a single po ion a e
2.5 ( o 12) o 3.5 d ( o 9a/b) o shaking.
Following bio ans o ma ion ( e e men a ion) o p oansami-
ocin de i a i e 12, only UPLC-ESIMS analysis o he silica-
gel- il e ed e hyl ace a e ex ac aken up in me hanol (see
abo e) was ca ied ou . The e en ion imes and mass spec a o
he de ec ed p oduc de i a i es 9b and 13b we e iden ical o
hose o he p e iously isola ed ma e ials (Suppo ing In o ma-
ion File 1).
Suppo ing In o ma ion
The suppo ing in o ma ion p o ides pu i ica ion p o ocols
o e men a ions, a sho desc ip ion o he cell p oli e a ion
assay, analy ical desc ip ions o new me aboli es and copies
o 1H and 13C NMR spec a.
Suppo ing In o ma ion File 1
Analy ical de ails and compound spec a.
[h p://www.beils ein-jou nals.o g/bjoc/con en /
supplemen a y/1860-5397-8-96-S1.pd ]
Acknowledgemen s
This wo k was suppo ed by he Deu sche Fo schungsgemein-
scha (G an Ki-397, 13-1) and he Fonds de Chemischen
Indus ie.
Re e ences
1. C agg, G. M.; G o haus, P. G.; Newman, D. J. Chem. Re . 2009, 109,
3012–3043. doi:10.1021/c 900019j
2. Newman, D. J.; C agg, G. M. J. Na . P od. 2007, 70, 461–477.
doi:10.1021/np068054
3. on Nussbaum, F.; B ands, M.; Hinzen, B.; Weigand, S.; Häbich, D.
Angew. Chem. 2006, 118, 5194–5254. doi:10.1002/ange.200600350
Angew. Chem. In . Ed. 2006, 45, 5072–5129.
doi:10.1002/anie.200600350.
4. Ki schning, A.; Hahn, F. Angew. Chem. 2012, 124, 4086–4096.
doi:10.1002/ange.201107386
Angew. Chem. In . Ed. 2012, 51, 4012–4022.
doi:10.1002/anie.201107386.
5. Weis , S.; Süssmu h, R. D. Appl. Mic obiol. Bio echnol. 2005, 68,
141–150. doi:10.1007/s00253-005-1891-8
6. Ki schning, A.; Ta , F.; Knobloch, T. O g. Biomol. Chem. 2007, 5,
3245–3295. doi:10.1039/b709549j
7. Kennedy, J. Na . P od. Rep. 2008, 25, 25–34. doi:10.1039/B707678A
8. Funayama, S.; Co dell, G. A. In S udies in Na u al P oduc Chemis y;
Rahman, A.-U., Ed.; Else ie Science B. V.: Ams e dam, 2000; Vol. 23,
pp 51–106.
9. Hamel, E. Pha macol. The . 1992, 55, 31–51.
doi:10.1016/0163-7258(92)90028-X
10. Cassady, J. M.; Chan, K. K.; Floss, H. G.; Leis ne , E.
Chem. Pha m. Bull. 2004, 52, 1–26. doi:10.1248/cpb.52.1
11. Ki schning, A.; Ha m ol s, K.; Knobloch, T. C. R. Chim. 2008, 11,
1523–1543. doi:10.1016/j.c ci.2008.02.006
12. Floss, H. G.; Yu, T.-W.; A akawa, K. J. An ibio . 2011, 64, 35–44.
doi:10.1038/ja.2010.139
13. Ta , F.; B ünjes, M.; Floss, H. G.; Czempinski, N.; G ond, S.;
Sasse, F.; Ki schning, A. ChemBioChem 2008, 9, 1057–1060.
doi:10.1002/cbic.200700742
14. Kubo a, T.; B ünjes, M.; F enzel, T.; Xu, J.; Ki schning, A.; Floss, H. G.
ChemBioChem 2006, 7, 1221–1225. doi:10.1002/cbic.200500506
15. Ta , F.; B ünjes, M.; Knobloch, T.; Floss, H. G.; Ki schning, A.
J. Am. Chem. Soc. 2009, 131, 3812–3813. doi:10.1021/ja8088923
Beils ein J. O g. Chem. 2012, 8, 861–869.
869
16. Knobloch, T.; Ha m ol s, K.; Ta , F.; Thomaszewski, B.; Sasse, F.;
Ki schning, A. ChemBioChem 2011, 12, 540–547.
doi:10.1002/cbic.201000608
17. Eichne , S.; Knobloch, T.; Floss, H. G.; Foh e , J.; Ha m ol s, K.;
He mane, J.; Schulz, A.; Sasse, F.; Spi elle , P.; Ta , F.; Ki schning, A.
Angew. Chem. 2012, 124, 776–781. doi:10.1002/ange.201106249
Angew. Chem. In . Ed. 2012, 51, 752–757.
doi:10.1002/anie.201106249.
18. Eichne , S.; Floss, H. G.; Sasse, F.; Ki schning, A. ChemBioChem
2009, 10, 1801–1805. doi:10.1002/cbic.200900246
19. Eichne , S.; Eichne , T.; Floss, H. G.; Foh e , J.; Ho e , E.; Sasse, F.;
Zeilinge , C.; Ki schning, A. J. Am. Chem. Soc. 2012, 134, 1673–1679.
doi:10.1021/ja2087147
20. Walsh, C. T.; Haynes, S. W.; Ames, B. D. Na . P od. Rep. 2012, 29,
37–59. doi:10.1039/c1np00072a
21. Spi elle , P.; Bai, L.; Shang, G.; Ca oll, B. J.; Yu, T.-W.; Floss, H. G.
J. Am. Chem. Soc. 2003, 125, 14236–14237. doi:10.1021/ja038166y
22. Yu, T.-W.; Bai, L.; Clade, D.; Ho mann, D.; Toelze , S.; T inh, K. Q.;
Xu, J.; Moss, S. J.; Leis ne , E.; Floss, H. G.
P oc. Na l. Acad. Sci. U. S. A. 2002, 99, 7968–7973.
doi:10.1073/pnas.092697199
23. A akawa, K.; Mülle , R.; Mahmud, T.; Yu, T.-W.; Floss, H. G.
J. Am. Chem. Soc. 2002, 124, 10644–10645. doi:10.1021/ja0206339
24. Yu, T.-W.; Mülle , R.; Mülle , M.; Zhang, X.; D äge , G.; Kim, C.-G.;
Leis ne , E.; Floss, H. G. J. Biol. Chem. 2001, 276, 12546–12555.
doi:10.1074/jbc.M009667200
25. Meye , A.; B ünjes, M.; Ta , F.; F enzel, T.; Sasse, F.; Ki schning, A.
O g. Le . 2007, 9, 1489–1492. doi:10.1021/ol0702270
26. F enzel, T.; B ünjes, M.; Qui schalle, M.; Ki schning, A. O g. Le . 2006,
8, 135–138. doi:10.1021/ol052588q
27. Ha m ol s, K.; B ünjes, M.; D äge , G.; Floss, H. G.; Sasse, F.; Ta , F.;
Ki schning, A. ChemBioChem 2010, 11, 2517–2520.
doi:10.1002/cbic.201000422
28. Moss, S. J.; Bai, L.; Toelze , S.; Ca oll, B. J.; Mahmud, T.; Yu, T.-W.;
Floss, H. G. J. Am. Chem. Soc. 2002, 124, 6544–6545.
doi:10.1021/ja020214b
29. Bandi, S.; Kim, Y. J.; Sa, S. O.; Chang, Y.-K. J. Mic obiol. Bio echnol.
2005, 15, 930–937.
30. Chung, J.; Byng, G. S. Mu an Ac inosynnema p e iosum s ain wi h
inc eased may ansinoid p oduc ion. U.S. Pa en 6,790,954, Sep 14,
2004.
Use o SAG 471 an i- oam o e men a ion o A. p e iosum was
sugges ed.
License and Te ms
This is an Open Access a icle unde he e ms o he
C ea i e Commons A ibu ion License
(h p://c ea i ecommons.o g/licenses/by/2.0), which
pe mi s un es ic ed use, dis ibu ion, and ep oduc ion in
any medium, p o ided he o iginal wo k is p ope ly ci ed.
The license is subjec o he Beils ein Jou nal o O ganic
Chemis y e ms and condi ions:
(h p://www.beils ein-jou nals.o g/bjoc)
The de ini i e e sion o his a icle is he elec onic one
which can be ound a :
doi:10.3762/bjoc.8.96